Drug prediction based on PCUGs and PCDGs revealed that several approved drugs (selumetinib, vorinostat, crizotinib, and palbociclib) for specific cancer types might be effective as pan-cancer treatments, similar to the widely used pan-cancer drugs like the PD-1 inhibitor Pembrolizumab (Keytruda), which is approved for any solid tumor with high microsatellite instability or mismatch repair deficiency, and larotrectinib (Vitrakvi), which is approved for solid tumors with neurotrophic receptor tyrosine kinase gene fusion. The gene discussed is NTRK1; the disease is mismatch repair cancer syndrome 1.